Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers

Clinical Pharmacokinetics

Volumn 37, Issue 2, 1999, Pages 167-176

  Brown, Frances ^a   Banken, Ludger ^b   Saywell, Kay ^a   Arum, Inger ^c  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ProTrials Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; GANCICLOVIR DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOMEGALIC INCLUSION BODY DISEASE; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; FEMALE; FLATULENCE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 0032873150     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937020-00005     Document Type: Article

References (14)

1. Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992: 14: 608-15
2. Polis MA, Masur H. Cytomegalovirus infection in patients with HIV infection. In: Broder S, Merigan TC, Bolognesi D, editors. Text book on AIDS medicine. Baltimore: Williams & Wilkin, 1994: 359-71
3. Stratta RJ. Clinical patterns and treatment of cylomegalovirus infection after solid-organ transplantation. Transplant Proc 1993; 25 Suppl. 4: 15-21
4. Holland GN, Sidikaro Y, Kreiger AE, et al. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987; 94: 815-23
5. Jabs, DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107: 75-80
6. Murray BM. Management of cytomegalovirus infection in solid-organ transplant recipients. Immunol Invest 1997; 26: 243-55
7. Follansbee S, Busch D, Connor J, et al. Phase I study of the safety and pharmacokinetics of oral ganciclovir [abstract no. F.B. 91]. Proceedings of the Sixth International Conference on AIDS: 1990 Jun 20-23: San Francisco. San Francisco: University of California, 1990, 6 (2): 112
8. Anderson RD, Griffy KG, Jung D, et al. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000 mg/day dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1995; 17: 425-32
9. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Mod 1995; 333: 615-20
10. Gane E, Saliba F, Valdecasas JC, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350; 1729-33
11. Dhillon B, Kamal A, Leen C. Intravitreal sustained-release ganciclovir implantation to control cytomegalovirus retinitis in AIDS. Int J STD AIDS 1998; 9: 227-30
12. Jung D, Dorr A. Single dose pharmacokinetics of valganciclovir in HIV- and CMV-seropostive subjects. J Clin Pharmacol. In press
13. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetics, safely and antiviral profiles of oral ganciclovir in persons infected with Human Immunodeficiency Virus: A phase I/II study. J Infect Dis 1995: 171: 1431-7
14. F. Hoffmann-La Roche, 1998. (Data on file)